American Journal of Cardiology
Volume 103, Issue 7 , Pages 1032-1038 , 1 April 2009

B-Type Natriuretic Peptides and Their Relation to Cardiovascular Structure and Function in a Population-Based Sample of Subjects Aged 70 Years

  • Kai M. Eggers, MD, PhD

      Affiliations

    • Department of Medical Sciences, Cardiology and Uppsala Clinical Research Center, Uppsala, Sweden
    • Corresponding Author InformationCorresponding author: Tel: 46-18-611-00-00; fax: 46-18-50-66-38
    • ,
  • Bertil Lindahl, MD, PhD

      Affiliations

    • Department of Medical Sciences, Cardiology and Uppsala Clinical Research Center, Uppsala, Sweden
    • ,
  • Per Venge, MD, PhD

      Affiliations

    • Department of Medical Sciences, Clinical Chemistry, Uppsala University Hospital, Uppsala, Sweden
    • ,
  • Lars Lind, MD, PhD

      Affiliations

    • Department of Medical Sciences, Medicine, Uppsala University Hospital, Uppsala, Sweden

Received 19 October 2008 ,Revised 12 December 2008 ,Accepted 12 December 2008.

References 

  1. Chong AY, Blann AD, Patel J, Freestone B, Hughes E, Lip GY. Endothelial dysfunction and damage in congestive heart failure (Relation of flow-mediated dilation to circulating endothelial cells, plasma indexes of endothelial damage, and brain natriuretic peptide). Circulation. 2004;110:1794–1798
  2. Abdullah SM, Khera A, Das SR, Stanek HG, Canham RM, Chung AK, et al. Relation of coronary atherosclerosis determined by electron beam computed tomography and plasma levels of N-terminal pro-brain natriuretic peptide in a multiethnic population-based sample (The Dallas Heart Study). Am J Cardiol. 2005;96:1284–1289
  3. Ninomiya Y, Hamasaki S, Ishida S, Kataoka T, Saihara K, Okui H, et al Elevated levels of brain natriuretic peptide as a predictor of impaired coronary endothelial function in patients with left ventricular remodelling. J Cardiol. 2006;48:125–132
  4. Lind L, Fors N, Hall J, Marttala K, Stenborg A. A comparison of three different methods to evaluate endothelium-dependent vasodilatation in the elderly (The Prospective Investigation of the Vasculature in Uppsala Seniors (PIVUS) Study). Arterioscler Thromb Vasc Biol. 2005;25:2368–2375
  5. Eggers KM, Lind L, Ahlström H, Bjerner T, Ebeling Barbier C, Larsson A, et al. Prevalence and pathophysiologic mechanisms of elevated cardiac troponin I levels in a population-based sample of elderly subjects. Eur Heart J. 2008;18:2252–2258
  6. Levey AS, Greene T, Kusek JW, Beck GJ MDRD Study Group. A simplified equation to predict glomerular filtration rate from serum creatinine. J Am Soc Nephrol. 2000;11:155A
  7. Lang RM, Bierig M, Devereux RB, Flachskampf FA, Foster E, Pellikka PA, et al Recommendations for chamber quantification: a report from the American Society of Echocardiography's Guidelines and Standards Committee and the Chamber Quantification Working Group, developed in conjunction with the European Association of Echocardiography, a branch of the European Society of Cardiology. J Am Soc Echocardiogr. 2005;18:1440–1463
  8. Devereux RB, Dahlöf B, Levy D, Pfeffer MA. Comparison of enalapril versus nifedipine to decrease left ventricular hypertrophy in systemic hypertension (the PRESERVE trial). Am J Cardiol. 1996;78:61–65
  9. Lind L, Fors N, Hall J, Marttala K, Stenborg A. A comparison of three different methods to determine arterial compliance in the elderly: the Prospective Investigation of the Vasculature in Uppsala Seniors (PIVUS) study. J Hypertens. 2006;24:1075–1082
  10. Vasan RS, Benjamin EJ, Larson MG, Leip EP, Wang TJ, Wilson PW, et al. Plasma natriuretic peptides for community screening for left ventricular hypertrophy and systolic dysfunction: the Framingham study. JAMA. 2002;288:1252–1259
  11. Abhayaratna WP, Marwick TH, Becker NG, Jeffery IM, McGill DA, Smith WT. Population-based detection of systolic and diastolic dysfunction with amino-terminal pro-B-type natriuretic peptide. Am Heart J. 2006;152:941–948
  12. Costello-Boerrigter LC, Boerrigter G, Redfield MM, Rodeheffer RJ, Urban LH, Mahoney DW, et al. Amino-terminal pro-B-type natriuretic peptide and B-type natriuretic peptide in the general community (Determinants and detection of left ventricular dysfunction). J Am Coll Cardiol. 2006;47:345–353
  13. Wallace TW, Abdullah SM, Drazner MH, Das SR, Khera A, McGuire DK, et al. Prevalence and determinants of troponin T elevation in the general population. Circulation. 2006;113:1958–1965
  14. Jeremias A, Gibson M. Narrative review: alternative causes for elevated cardiac troponin levels when acute coronary syndromes are excluded. Ann Intern Med. 2005;142:786–791
  15. Madhani M, Scotland RS, MacAllister RJ, Hobs AJ. Vascular natriuretic peptide receptor-linked particulate guanylate cyclises are modulated by nitric oxide-cyclic GMP signalling. Br J Pharmacol. 2003;139:1289–1296
  16. Vita JA. Endothelial function and outcome. Heart. 2005;91:1278–1279
  17. Tateishi J, Masutani M, Ohyanagi M, Iwasaki T. Transient increase in plasma brain (B-type) natriuretic peptide after percutaneous transluminal coronary angioplasty. Clin Cardiol. 2000;23:776–780
  18. Hammerer-Lercher A, Ludwig W, Falkensammer G, Müller S, Neubauer E, Puschendorf B, et al. Natriuretic peptides as markers of mild forms of left ventricular dysfunction: effects of assays on diagnostic performance of markers. Clin Chem. 2004;50:1174–1183

 This work was supported by the Swedish Research Council, Stockholm, Sweden (Grant K2003-71X-00676-21A) and The Linné Foundation for Medical Research, Uppsala, Sweden. Dr. Lind received a research grant from AstraZeneca, Mölndal, Sweden.

PII: S0002-9149(08)02212-1

doi: 10.1016/j.amjcard.2008.12.014

American Journal of Cardiology
Volume 103, Issue 7 , Pages 1032-1038 , 1 April 2009

Article Tools

* Image Usage & Resolution